Phase III hit heralds new hope for hemophilia treatment

Positive results from the Phase III BASIS study show the potential of Pfizer’s (NYSE: PFE) novel hemophilia therapy marstacimab.

The US Food and Drug Administration (FDA) Fast Track-designated antibody is being developed for people with hemophilia A or B, without inhibitors to Factor VIII or Factor IX.

The BASIS study met its primary endpoints, generating a statically-significant and clinically-meaningful effect when given subcutaneously on a weekly basis.